Join our community of smart investors

Biogen decision could mark a big shift for big pharma

Beyond the immediate impact for Biogen, the US regulator's decision could have repercussions for the broader pharma sector
Biogen decision could mark a big shift for big pharma

 

  • Biogen has filed findings for its Alzheimer's clinical trial with the FDA
  • A landmark case for US regulators and their first major test under the Biden administration

The successful results reported by US pharma group Biogen (US: BIIB) in the clinical study of its Alzheimer’s drug aducanumab have been compared to “firing a shotgun at a barn door and then drawing a target around the bullet holes.”

It’s not a completely unfair criticism. Scientists working on the clinical trial initially concluded that it had been unsuccessful in slowing the progression of Alzheimer’s Disease - the leading cause of dementia - before retracting their early comments after finding that patients who had been given a higher dosage showed good signs of progress. A subsequent trial found that aducanumab has the potential to slow the underlying disease pathology and cognitive decline in patients with mild symptoms. 

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in